Decoding the Hype and Fear of Nanomedicines - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Decoding the Hype and Fear of Nanomedicines
Does nanotechnology offer a cure-all or a kill all? We speak with Ruth Duncan about the real potential of nanomedicines.


Pharmaceutical Technology Europe
Volume 24, Issue 2

Q: Nanotechnology is often hyped as either a miracle cure-all or a potential danger. How much of this is grounded in truth and what is the practical reality of the technology?


(VICTOR HABBICK VISIONS/GETTY IMAGES)
The rational design of advanced drug delivery systems and innovative nano-sized therapeutics (nanomedicines) began almost half a century ago. There are already more than 40 products approved by regulatory agencies for routine use, and many more technologies are also in clinical development. These first-generation products are making an important contribution and are seen to be safe and efficacious with an adequate risk–benefit. Follow-on products are also starting to emerge, as well as novel second-generation nanotechnologies that can be used as therapeutics, imaging agents and combined theranostics.

Innovative nanoscience in concert with the increased knowledge arising from genomics and proteomics research is creating exciting opportunities for nanomedicine development using advances in materials science and, in some cases, innovative therapeutics such as siRNA and aptamers. There is also real potential to develop novel multicomponent systems (e.g., those involving gold or iron nanoparticles, and polymers and therapeutics as single agents or combination therapies). More in depth discussion about the opportunities and challenges in these areas can be read in a Duncan and Gaspar paper (1).

Q: What new therapies can nanotechnology enable?

To answer this question, I advise readers to take a look at an interesting historical overview by B. Munos (2). He explains that during the last 60 years, the FDA has approved approximately 1200 new chemical entities, as well as around 120 biologicals/proteins. Roughly 40 nanomedicine products have also reached the market, which is interesting given the relatively minor investment of pharma companies in this area compared with that for low-molecular weight chemical entities and biotech products.

In the coming years, I believe we will see an increasing number of nanomedicine products. Consider for instance that low-molecular weight synthetic chemotherapy was only born at the beginning of the last century.

In my view, some of the particularly interesting opportunities/advances in nanomedicines include:

  • A combination therapy with liposomes containing two drugs is already in Phase I/II development by Celator Pharmaceuticals (US).
  • Polymer therapeutics—several polymeric drugs, polymer-proteins/polymer aptamer and block copolymer micelles are now on the market and there is a strong pipeline for further clinical development
  • New manufacturing techniques and template manufacturing (PRINT approach) that are applicable to many areas of advanced drug delivery. Interesting insight can be read in a Petros and DeSimone paper (3).
  • New opportunities for intracellular/cytosolic delivery of macromolecular therapeutics.
  • Continuing efforts to improve the delivery of poorly soluble or unstable drugs, improve disease specific targeting and create new technologies for vaccine delivery.

Q: How fast (or slow) has the pharma industry been to embrace nanotechnology?

The 40 or so first-generation nanomedicines on the market began to arrive in 1990 and now there are many follow-up products and novel nanotechnology approaches in pipelines. In particular, specific technologies, such as nanocrystals, have been rapidly embraced over the last decade because they can help solve specific formulation challenges, such as poor water solubility.

When all these technologies emerged as first in class, they were, as with any new, high-risk technology, embraced very slowly by pharma companies. However, once a technology has arrived in the market, there is always a sudden burst of interest, particularly as some products gain blockbuster status. With nanotechnology now well established, coupled with the high-drug attrition rate for low-molecular weight chemical entities, interest in this area has certainly increased.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology Europe,
Click here